Somatic gain-of-function mutations in PIK3CA, determining a constitutive activation of the PI3K/AKT/mTOR pathway, are among the main driver mechanisms in cancer and are also responsible for benign overgrowth syndromes, collectively known as PIK3CA-related overgrowth spectrum (PROS) disorders (1). This evidence concerns the gene MTOR and cancer.